Should We Rewrite the Human Genome?
By Alex Harding,
Xconomy
| 11. 28. 2016
Scientists are engineering a new living thing: a radically modified version of the lowly bacterium E. coli. In an article in Science from August, researchers at Harvard University described an ongoing project to build the genetic code of E. coli from scratch, but with major revisions to create a new strain unlike any in existence.
The modified E. coli is meant to be so foreign to viruses that they will not be able to infect it. George Church, the principal investigator on the study, told me the finished product “will be completely, unassailably resistant to all viruses, even viruses never seen before.” This offers important advantages in industrial processes such as pharmaceutical and biofuel manufacturing, said Matthieu Landon, one of the lead authors on the paper. (Genzyme, a biotechnology company, suffered a crippling viral contamination in 2009 at its Allston, MA, plant that made two essential drugs unavailable for the patients who depended upon them. A virus-resistant cell would not be vulnerable to such contamination.)
The E. coli project is a step toward the synthesis of a human genome...
Related Articles
By Rob Stein, NPR [cites CGS' Katie Hasson] | 08.06.2025
A Chinese scientist horrified the world in 2018 when he revealed he had secretly engineered the birth of the world's first gene-edited babies.
His work was reviled as reckless and unethical because, among other reasons, gene-editing was so new...
By Susanna Smith, Genetic Frontiers | 07.28.2025
Key Topics
How does the American far right view genetics and genetic technologies?
What is the history of the American cultural pursuit of trying to choose smarter children? What has science shown us about the relationship of heredity and intelligence...
By Arthur Caplan and James Tabery, Scientific American | 07.28.2025
An understandable ethics outcry greeted the June announcement of a software platform that offers aspiring parents “genetic optimization” of their embryos. Touted by Nucleus Genomics’ CEO Kian Sadeghi, the $5,999 service, dubbed “Nucleus Embryo,” promised optimization of...
By John H. Evans, Craig Callender, Neal K. Devaraj, Farren J. Isaacs, and Gregory E. Kaebnick, Issues in Science and Technology | 07.04.2025
The controversy around a ban on “mirror life” should lead to a more nuanced public conversation about how to manage the benefits and risks of precursor biotechnologies.
About five years ago, the five of us formed a discussion group to...